Document is current
Any future updates will be listed below
-
Authors
Fattizzo, Bruno https://orcid.org/0000-0003-0857-8379
Schmidt, Christoph Q.
-
Funding
Funding for this research was provided by:
Ministero della Salute
Universität Ulm
- License Information
-
More Information
Article History
Received: 29 October 2025
Revised: 26 February 2026
Accepted: 27 February 2026
First Online: 14 March 2026
Declarations
:
: B.F. received consultancy and speaker honoraria from Alexion, AstraZeneca, Novartis, Roche, Sanofi, and Sobi. BF received research funds from Agios Pharmaceuticals and Zenas Biopharma. C.Q.S. is a named inventor of patent applications that describe the use of complement inhibitors for therapeutic applications. C.Q.S. has received research funding from pharmaceutical companies, honoraria for speaking at symposia organized by Alexion Pharmaceuticals, Sobi and Sanofi, and serving on an advisory committee for Sobi.
